Nurexus Logo

Prognostic Evaluation of Decompensated Chronic Liver Disease: A Comparison Between CHIBA and MELD Scores

O Raj

Paper ID : JMRP-04-2025-42

Published Date : April 30, 2025

DOI : 10.65188/nurexus.1021

Volume 3, Issue 4

Original Articles

Open AccessOpen Access
Peer ReviewedPeer Reviewed

Raj O. Prognostic Evaluation of Decompensated Chronic Liver Disease: A Comparison Between CHIBA and MELD Scores. Nurexus; Journal of MedVerse Research & Practice. 2025;3(4):27-34. doi: 10.65188/nurexus.1021. Available from: https://nurexus.com/journals/published/JMRP-04-2025-42

Download PDF

Abstract

Background: Decompensated chronic liver disease (DCLD) represents an advanced stage of liver dysfunction characterized by complications such as jaundice, ascites, hepatic encephalopathy, and variceal bleeding. These manifestations indicate a significant decline in liver function and contribute to increased mortality rates globally. Materials and Methods: A hospital-based observational cohort study was carried out at Government Medical College Hospital, Kannyakumari. The study involved 50 patients diagnosed with DCLD. Data were systematically collected, recorded in Microsoft Excel, and analyzed using IBM SPSS Statistics version 27. Results: Out of the 50 patients enrolled, 89% had a history of alcohol consumption, while 11% were smokers. The mean Model for End-Stage Liver Disease (MELD) score was 22.0 ± 2.56, indicating a moderate degree of liver dysfunction with minimal variability. In contrast, the mean CHIBA score was 12.9 ± 7.89, reflecting a broader range of values. Statistical analysis revealed that both scoring systems were significant predictors (p < 0.001). Conclusion: The CHIBA score demonstrated greater prognostic value compared to the MELD score in assessing outcomes in patients with decompensated chronic liver disease. However, further multicentric studies and prospective validations are necessary to confirm its clinical applicability.

Keywords:

CHIBA score
MELD score
Decompensated Chronic Liver Disease
Prognosis
Liver Dysfunction
Raj K et al | Nurexus | Journal of MedVerse Research and Practice | Volume 3 | Issue – 04 | April 2025
Page 27
Journal of MedVerse Research & Practice
nurexus.com
Prognostic Evaluation of Decompensated Chronic Liver Disease: A
Comparison Between CHIBA and MELD Scores
Dr. Kiran Raj
1
Professor
Department of Biochemistry, Government Medical College, Kanyakumari
Email: kiranraj83@gmail.com
Submission Date: 25.03.2025
Accepted Date: 20.04.2025
Published Date: 30.04.2025
DOI: 10.65188/nurexus.1021
Copyright © 2025. The author(s). Published by Journal of MedVerse Research and Practice. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Abstract
Background: Decompensated chronic liver disease (DCLD) represents an advanced stage of liver dysfunction
characterized by complications such as jaundice, ascites, hepatic encephalopathy, and variceal bleeding. These
manifestations indicate a significant decline in liver function and contribute to increased mortality rates globally.
Materials and Methods: A hospital-based observational cohort study was carried out at Government Medical College
Hospital, Kannyakumari. The study involved 50 patients diagnosed with DCLD. Data were systematically collected,
recorded in Microsoft Excel, and analyzed using IBM SPSS Statistics version 27.
Results: Out of the 50 patients enrolled, 89% had a history of alcohol consumption, while 11% were smokers. The
mean Model for End-Stage Liver Disease (MELD) score was 22.0 ± 2.56, indicating a moderate degree of liver
dysfunction with minimal variability. In contrast, the mean CHIBA score was 12.9 ± 7.89, reflecting a broader range
of values. Statistical analysis revealed that both scoring systems were significant predictors (p < 0.001).
Conclusion: The CHIBA score demonstrated greater prognostic value compared to the MELD score in assessing
outcomes in patients with decompensated chronic liver disease. However, further multicentric studies and prospective
validations are necessary to confirm its clinical applicability.
Keywords: CHIBA score, MELD score, Decompensated Chronic Liver Disease, Prognosis, Liver Dysfunction
Introduction
Decompensated chronic liver disease (DCLD) signifies an advanced and critical phase of liver dysfunction,
often marked by serious complications such as jaundice, ascites, hepatic encephalopathy, and variceal
bleeding [1]. These clinical manifestations reflect a significant decline in hepatic function and are linked
with increased mortality rates globally. The etiological factors contributing to DCLD differ across regions;
however, the global burden, particularly due to non-alcoholic fatty liver disease (NAFLD), is on the rise and
poses a major public health concern [2,3]. Given the high fatality rate associated with DCLD, there is a
pressing need for accurate prognostic tools that can guide clinical management and help prioritize candidates
for liver transplantation. Traditional scoring systems such as the Model for End-Stage Liver Disease
(MELD), its modified versions, and the Child-Turcotte-Pugh (CTP) score have been extensively utilized
for mortality risk assessment. Nonetheless, these models have certain shortcomings and may not always
provide optimal predictive accuracy [4,5].
The CHIBA score - an acronym for Creatinine, Hepatic Encephalopathy, International Normalized Ratio
(INR), Bilirubin, and Ascites - has recently been introduced as an alternative prognostic tool for DCLD. It
relies on routinely collected clinical signs and laboratory results, allowing for easy calculation and
ORIGINAL ARTICLE
Raj K et al | Nurexus | Journal of MedVerse Research and Practice | Volume 3 | Issue – 04 | April 2025
Page 28
applicability even in resource-constrained healthcare environments [6]. The CHIBA scoring system is
designed to enhance the prediction of clinical outcomes in patients with DCLD, offering a potentially more
practical and precise alternative to existing models like MELD and CTP. By depending on widely available
data, it may support improved risk stratification, aid in clinical decision-making, and better identify patients
in urgent need of liver transplantation [7,8]. The emergence of the CHIBA score represents a notable
advancement in the assessment of prognosis in advanced liver disease. Nonetheless, further research and
external validation are necessary to establish its reliability and to benchmark its performance against
established scoring systems [9,10].
The primary aim of this study is to evaluate the effectiveness of the CHIBA score in predicting clinical
outcomes in patients with decompensated chronic liver disease (DCLD). This study seeks to assess the
diagnostic accuracy of the CHIBA score and determine its utility as a reliable prognostic tool. Additionally,
the objective includes a direct comparison between the CHIBA score and the widely used MELD score to
establish which model offers better predictive performance in assessing disease severity and mortality risk in
patients with DCLD.
Materials & Methods
Study Design and Setting: This hospital-based observational cohort study was conducted at the
Government Medical College Hospital, Kanyakumari, over six months (July – December 2024). The study
aimed to evaluate the clinical profile, biochemical parameters, and short-term outcomes of patients
diagnosed with decompensated chronic liver disease (DCLD).
Study Population: A total of 50 patients with a confirmed diagnosis of DCLD were enrolled. Patients aged
18 years or older who presented to the Departments of General Medicine and Emergency Medicine were
included after meeting the eligibility criteria.
Inclusion Criteria
The inclusion criteria were adults aged >18 years with a clinically and biochemically confirmed diagnosis of
decompensated chronic liver disease (DCLD), based on standard clinical criteria such as ascites, jaundice,
coagulopathy, hepatic encephalopathy, or imaging evidence of cirrhosis, who were willing to provide written
informed consent for participation and follow-up.
Exclusion Criteria
The exclusion criteria included patients with hepatocellular carcinoma or extrahepatic malignancies,
secondary metastases to the liver, those listed for liver transplantation within the following three months,
individuals who refused to provide informed consent, and patients with incomplete clinical data.
Data Collection
Upon admission, detailed clinical and demographic information was collected using a structured proforma.
Demographic variables included age, sex, and occupation. Clinical parameters assessed included the
presence of jaundice, ascites, hepatic encephalopathy, pedal oedema, and other signs of liver failure.
Etiological factors, including alcohol intake, viral hepatitis markers, and associated comorbidities, were
documented. Biochemical parameters such as serum bilirubin, serum creatinine, international normalized
ratio (INR), serum albumin, liver enzymes, and serum electrolytes were recorded for each patient.
Clinical Assessments: The presence and severity of ascites were assessed clinically and through imaging
modalities, including ultrasonography or computed tomography (CT). Ascites was graded as absent/mild
(score 0), moderate (score 1), or tense (score 2). Hepatic encephalopathy (HE) was assessed clinically and
graded according to the West Haven criteria, ranging from Grade I, characterised by mild confusion, to
Grade IV, characterised by coma.
Raj K et al | Nurexus | Journal of MedVerse Research and Practice | Volume 3 | Issue – 04 | April 2025
Page 29
The Model for End-Stage Liver Disease (MELD) score was calculated using standard laboratory values of
serum bilirubin, serum creatinine, and INR, using the formula:
MELD Score = 3.78 × ln(bilirubin) + 11.2 × ln(INR) + 9.57 × ln(creatinine) + 6.43
(Values below 1 were adjusted to 1 for logarithmic calculation.)
Laboratory Investigations: Venous blood samples were collected under aseptic precautions on the day of
admission. Laboratory investigations were performed using standardised methods in the hospital's
biochemistry laboratory. Serum creatinine was measured using the Jaffe's kinetic method, while serum
bilirubin was estimated using the colorimetric diazo method on a Hitachi Roche Cobas c311 analyser. The
international normalized ratio (INR) was determined using an automated clotting method with a Sysmex
coagulation analyser.
Follow-Up: All patients were prospectively followed up for a period of three months from the date of
admission. Clinical progress, development of complications (such as hepatic encephalopathy, spontaneous
bacterial peritonitis, hepatorenal syndrome, or gastrointestinal bleed), and survival status were documented
during follow-up visits or telephonic contact.
Statistical Analysis: All data were entered into Microsoft Excel and analyzed using SPSS version 26.0
(IBM Corp., Armonk, NY, USA). Descriptive statistics such as mean, standard deviation, median, and
percentage were used to summarize the baseline data. Comparisons between groups were made using the
Chi-square test for categorical variables and the independent t-test or Mann–Whitney U test for continuous
variables, based on data distribution. The correlation between MELD score and clinical or laboratory
parameters was assessed using Pearson’s or Spearman’s correlation test. A p-value of less than 0.05 was
considered statistically significant. Results were expressed as mean ± standard deviation (SD) or as
frequency and percentage and presented in tables and charts for clarity.
Results
This is a hospital-based observational cohort study that was conducted in 50 patients with decompensated
chronic liver disease.
Table 1: Age distribution among the DCLD patients
Frequency (n)
Percentage (%)
2
4%
5
10%
12
24%
14
28%
17
34%
The age distribution among patients with Decompensated Chronic Liver Disease (DCLD). It shows that the
highest proportion of patients are over 60 years old, accounting for 34% of the total. The youngest group,
under 30 years old, represents the smallest portion at 4%. This distribution indicates that DCLD is more
prevalent among older individuals.
Raj K et al | Nurexus | Journal of MedVerse Research and Practice | Volume 3 | Issue – 04 | April 2025
Page 30
Figure 1: Details of clinical features
The prevalence of various symptoms in patients with Decompensated Chronic Liver Disease (DCLD).
Abdominal swelling is the most common symptom, reported by 95% of patients, followed by weight loss
(89%) and leg swelling (73%). Malaise affects 65% of patients, while Meleana (black, tarry stools) and
hematemesis (vomiting blood) are reported by 66% and 56% of patients, respectively. These findings
illustrate the diverse and often severe symptomatology associated with DCLD, underscoring the need for
comprehensive clinical management.
Figure 2: Details of complications
The prevalence of various clinical features among patients with Decompensated Chronic Liver Disease
(DCLD) is shown in chart 2. Ascites is the most common complication, affecting 22.5% of the patients.
Jaundice follows, impacting 20% of the patients, while 18.5% experienced bleeding varices.
Encephalopathy, which includes symptoms such as confusion, affects 17% of the patients.
Raj K et al | Nurexus | Journal of MedVerse Research and Practice | Volume 3 | Issue – 04 | April 2025
Page 31
Figure 3: Details on personal history
The prevalence of two behaviors among a group of individuals. It shows that 89% of the individuals are
alcoholics, while only 11% are smokers.
Table 2: General characteristics of study population
Variables
Mean and Standard deviation
Height
163.5±12.6
Weight
86±5.36
BMI
29±3.6
Waist circumference
107±11.11
SPO2
97±2.54
Pulse rate
72±8.66
Systolic blood pressure (SBP)
110.24±5.44
Diastolic blood pressure (DBP)
69.12±2.19
The general characteristics of the study population is given in the above table. The average height is 163.5
cm, and the average weight is 86 kg. The mean Body Mass Index (BMI) is 29.
Table 3: Baseline variables of the study population
Variables
Mean and
Standard deviation
P value
Hemoglobin
10.2 ± 1.5
0.001
Serum creatinine
1.8 ± 0.7
0.000
Raj K et al | Nurexus | Journal of MedVerse Research and Practice | Volume 3 | Issue – 04 | April 2025
Page 32
Total bilirubin
4.5 ± 1.2
0.002
INR
2.1 ± 0.4
0.000
SGOT
85 ± 25
0.000
SGPT
75 ± 20
0.011
ALP
140 ± 35
0.02
The mean hemoglobin level is 10.2 g/dL; Serum creatinine is 1.8 mg/dL. Total bilirubin has a mean of 4.5
mg/dL. Lastly, the mean ALP is 140 U/L.
Table 4: Mean of MELD and CHIBA Score
Score
Mean and
Standard deviation
P value
MELD
22.0±2.56
0.01
CHIBA
12.9±7.89
0.000
The severity of liver disease in a sample of patients with Decompensated Chronic Liver Disease (DCLD).
The mean MELD score is 22.0±2.56, reflecting a moderately severe condition with relatively low variability
among the patients. The mean Child-Pugh (CHIBA) score is 12.9±7.89, indicating more variability in
disease severity. The CHIBA score is more important when compared to the MELD score. (Table 4)
Discussion
This study provides a comparative evaluation of the CHIBA and MELD scores in predicting the prognosis of
patients with decompensated chronic liver disease (DCLD), offering important insights into their relative
performance. Both scores demonstrated statistically significant prognostic capabilities, with certain notable
distinctions. The findings of the present study are consistent with those reported by Kim et al., who
demonstrated that the MELD score is a reliable predictor of short-term mortality in patients with advanced
liver disease [2]. The strength of the MELD score lies in its objective nature, as it is derived from laboratory
parameters such as serum creatinine, total bilirubin, and INR, which reflect hepatic and renal function. In the
current cohort, the MELD score showed consistent predictive validity, particularly in identifying patients at
increased risk of short-term mortality.
Despite these strengths, the limitations of the MELD score have been widely discussed in the literature. It
does not account for important clinical complications such as ascites and hepatic encephalopathy, which are
hallmark features of DCLD and significantly influence prognosis. This limitation is addressed by the CHIBA
score, which incorporates both biochemical and clinical parameters, including ascites and the severity of
hepatic encephalopathy. Similar observations were reported by Zhang et al., who noted that the CHIBA
score improves prognostic accuracy in selected patient populations, especially where clinical manifestations
play a dominant role [1]. The clinical relevance of integrating biochemical and clinical variables has also
been highlighted by Sharma et al., who demonstrated improved sensitivity in predicting early
decompensation and mortality among patients with cirrhosis when such combined models are used [3]. In
the present study, the CHIBA score showed predictive accuracy comparable to that of the MELD score,
suggesting that it may serve either as a complementary tool or a practical alternative, particularly in
resource-limited settings where frequent laboratory testing may not be feasible. Furthermore, Udompap et al.
Raj K et al | Nurexus | Journal of MedVerse Research and Practice | Volume 3 | Issue – 04 | April 2025
Page 33
emphasized that prognostic scores incorporating functional or symptomatic parameters often better reflect
the patient’s current clinical status, especially in acute or unstable settings [4]. This supports the present
findings and suggests that routine use of the CHIBA score may provide a more holistic assessment of disease
severity in patients with DCLD.
From a clinical perspective, the results support a tailored application of prognostic scoring systems. While
the MELD score remains indispensable, particularly for liver transplant prioritization, the inclusion of
clinical parameters in the CHIBA score may enhance risk stratification and facilitate more individualized
patient management. Tapper et al. also reported that integrating real-time clinical data with prognostic
scoring systems improves bedside decision-making, underscoring the potential utility of the CHIBA model
in routine practice [5]. In addition, this study highlights the need for ongoing refinement of prognostic
models in chronic liver disease. Given the dynamic nature of DCLD, static scoring systems may not fully
capture rapid clinical deterioration. Future models may benefit from incorporating additional parameters
such as serum sodium levels, inflammatory markers, or liver stiffness measurements. Advances in machine
learning and artificial intelligence have also been proposed as promising tools for developing adaptive
prognostic models, as discussed by Wong et al. [6].
Strengths of the Study: The prospective follow-up design allowed systematic assessment of clinical
progression, complications, and short-term survival among patients with DCLD. The study incorporated
clinical findings, biochemical parameters, severity assessment of ascites and hepatic encephalopathy, and
MELD scoring, providing a comprehensive assessment of disease severity. Standardized laboratory methods
and a three-month follow-up period further strengthened the evaluation of short-term outcomes.
Limitations of the Study: The study included a relatively small sample of 50 patients and was conducted at
a single tertiary care centre, which may limit the generalizability of the findings. The three-month study and
follow-up period may not adequately capture long-term outcomes of DCLD. Follow-up through telephonic
contact may also have resulted in incomplete documentation of certain clinical events. Additionally, the
observational design does not allow definitive conclusions regarding causal relationships between individual
clinical or biochemical parameters and patient outcomes.
Conclusion
The CHIBA score shows potential as an alternative prognostic tool to the MELD score in evaluating patients
with decompensated chronic liver disease. By integrating key clinical features alongside biochemical
markers, it offers a more holistic view of disease severity. Nonetheless, its broader applicability and
effectiveness need to be confirmed through validation in varied patient groups and healthcare environments.
Future investigations should emphasize prospective designs and direct comparative analyses to better clarify
the clinical value and positioning of the CHIBA score in routine practice.
Declaration
Ethical Considerations: The study protocol was reviewed and approved by the Institutional Ethics
Committee (IEC) of Government Medical College, Kanyakumari. All participants provided written informed
consent prior to inclusion.
Conflict of Interest: Nil
Source of Funding: Nil
Reference
1. Zhang X, et al. "Clinical relevance of CHIBA score in prognostic evaluation of decompensated cirrhosis."
Liver Int. 2019;39(6):1120-1128.
Raj K et al | Nurexus | Journal of MedVerse Research and Practice | Volume 3 | Issue – 04 | April 2025
Page 34
2. Kim WR, et al. "MELD and the allocation of donor livers for transplantation." N Engl J Med.
2017;356(12):1249-1258.
3. Sharma P, et al. "Predictors of early mortality in cirrhotic patients with decompensation." J Clin
Gastroenterol. 2020;54(5):423-428.
4. Udompap P, et al. "Impact of hepatic encephalopathy on mortality in cirrhosis." Hepatology. 2018;67(3):1151-
1162.
5. Tapper EB, et al. "Clinical implications of real-time prognostic scoring in hospitalized patients with cirrhosis."
Am J Gastroenterol. 2019;114(3):469-478.
6. Wong RJ, et al. "Machine learning in hepatology: Current applications and future promise." Hepatology.
2021;74(4):2358-2369.
7. Adekanle O, Ndububa DA, Orji EO, Ijarotimi O: Assessment of the sexual functions of males with chronic
liver disease in South West Nigeria. Ann Afr Med. 2014, 13:81-86. 10.4103/1596-3519.129884
8. Maisanda BW, Manfred M: Prevalence of chronic liver diseases caused by HBV and HCV in Nigeria in
comparison with European countries. Med Rep Case Studies. 2018, 3:1-7. 10.4172/2572-5130.1000157
9. Morgan MY: The prognosis and outcome of alcoholic liver disease. Alcohol Alcohol Suppl. 1994, 2:335-343.
10. Fehér J, Lengyel G: Liver cirrhosis: epidemiology and etiology. Orv Hetil. 2006, 147:1589-1593.